- Moderna sees revenue bump from international COVID vaccine salesThe company is making up for a decline in U.S. vaccine sales with better results elsewhere, continuing a turnaround that’s vaulted its stock price in 2026.BioPharma Dive · 2mo ago↗ source
- Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookInvestors are still waiting to see whether Bristol Myers and Regeneron’s pipelines will deliver, while Biogen was lifted by better-than-expected results for newer drugs like Leqembi and Skyclarys.BioPharma Dive · 2mo ago↗ source
- Two biotechs raise a combined $556M in latest spurt of IPOsSeaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a stretch of large IPOs this year that collectively raised almost $3.2 billion.